Connect with us

Cannabis

Core One Labs Inc. Announces Start of Construction on the Highway 395 Dispensary Project

Published

on

Reading Time: 1 minute

 

Core One Labs Inc. (CSE: COOL), (OTCQX: LDSYD), (Frankfurt: LD6, WKN: A14XHT) (“COOL” or the “Company”) announces that its wholly-owned subsidiary, LDS Development Corporation, has received grading permits and broke ground on the Highway 395 Dispensary project. The Adelanto Mayor, Gabriel Reyes, City Manager, Jessie Flores, and members of the City Council were all in attendance with shovels for the ground breaking.

The Highway 395 Dispensary project represents the final tier of the vertical integration for Core One Labs Inc. from plant genetics, cultivation, extraction, distillation, and manufacturing of cannabis products to direct delivery to the customer. The Dispensary site is located on Rancho Road and the 395 Highway in Adelanto, California, with a clear view for 120,000 passing vehicles each day.

The completion of the Highway 395 Dispensary will allow for benefits far beyond just the financial considerations created by the additional profit centers of online orders, in-store sales, direct delivery to customers, and reducing or eliminating margins paid to third parties. This dispensary will allow Core One Labs to donate CannaStripsTM to hospitals and medical organizations in the hopes of gathering much-needed research and documentation in professional environments.

Core One Labs CEO, Brad Eckenweiler, stated, “The completion of the Highway 395 Dispensary will complete the final piece of our mission to be fully integrated from genetics to the customer’s doorstep. We will be controlling product quality and customer service at every level because today, success does not depend on just having a good product. Customer experience, great product, ease of ordering, and home delivery all play major roles in a company’s ultimate success.”

Cannabis

Sunniva Announces Closing Of Third Tranche Of Short Term Bridge Financing For Proceeds Of Cad $325,000

Published

on

Reading Time: 2 minutes

 

Sunniva Inc. (“Sunniva”, the “Company”, “we”, “our” or “us”) (CSE:SNN) (OTCQB:SNNVF), a North American provider of cannabis products and services, is pleased to announce that it has closed the third tranche of the Company’s non-brokered private placement (the “Offering“), previously announced on August 1, 2019 of CAD $325,000 for a total of 325,000 units of the Company (“Units“). In aggregate the total gross proceeds raised by the Offering was CAD $7.57 million and 7.57 million Units issued. Each Unit consists of a principal amount of unsecured promissory notes of the Company (“Promissory Notes“) and common share purchase warrants of the Company (“Warrants“).

As previously disclosed, proceeds of the Offering will be used to provide short term working capital for operations in California, capital costs at the Sunniva California Campus and general corporate purposes.

The Units issued under the Offering have the following terms:

Promissory Notes  

     Maturity: 

6 months from the closing date.

     Interest Rate:

10% (annual rate).

Warrants 

     Number of Warrants:   

0.40 Warrants per Unit (each Warrant entitles the holder to acquire one common

share of the Company at the Warrant Exercise Price).

     Warrant Exercise Price:  

CAD $2.50 per Warrant.

     Warrant Term:         

24 months from closing.

A finder’s fee of 5% payable in cash will be paid to certain investment advisors for introducing certain purchasers of Units to the Company.

The Promissory Notes and Warrants have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Promissory Notes or Warrants in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

For more information please visit: www.sunniva.com.

To be added to the Sunniva email distribution list please register at www.sunniva.com/email-alerts.mailto:

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE Sunniva Inc.

Continue Reading

Cannabis

Prairie Records Tops the Charts: Named Top Cannabis Retailer in Canada at Grow UP

Published

on

Reading Time: 1 minute

 

Westleaf Inc. (the “Company” or “Westleaf“) (TSX-V:WL) (OTCQB:WSLFF) is proud to announce its Prairie Records retail stores have been named top cannabis retailer in Canada at the GrowUP Conference & Expo. Singing a different tune in cannabis retail, the award win is a testament to how Prairie Records is offering Canadian’s a truly unprecedented purchasing experience.

“It is extremely gratifying to have Prairie Records be recognized at one of the industry’s largest events and to be able to stand out amongst a field of very worthy retail competitors,” says Adam Coates, Chief Commercial Officer at Westleaf and Retail Brand Strategist for Prairie Records. “We set out to make waves in a sea of sameness by creating an immersive experience like no other in the marketplace, and we are pleased and honoured to receive this, the first Grow UP Conference retail award.”

Ten companies were nominated in the Grow UP retail category at this year’s event, the first for the industry. Among the nominees were independent stores and well-known national chains. Prairie Records was recognized based on delivering an unparalleled consumer purchasing experience and creating a welcoming brand for cannabis consumers.

Westleaf has four Prairie Records stores open, three in the Saskatoon region and one in Calgary, which is hosting its grand opening tomorrow, September 14. The concept combines the tactile and immersive feel of a vinyl record store with a cannabis purchasing experience. Information about the cannabis strains and strengths are presented on album covers and the customer is enveloped in a warm and welcoming retail experience. The staff are well versed on the product offering and provide educational opportunities for both the experienced cannabis connoisseur as well as the novice consumer.

 

SOURCE Westleaf Inc.

Continue Reading

Cannabis

INTERCURE: CANNDOC signs strategic distribution agreement with S.L.E. of TEVA Pharmaceuticals

Published

on

Reading Time: 2 minutes

 

InterCure (TASE: INCR), announced that subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein (S.L.E.,) which is owned by Teva Pharmaceuticals Industries (NYSE: and TASE: TEVA).

Under terms of the agreement, S.L.E. will distribute Canndoc’s GMP products to pharma clients, including hospitals, health maintenance organizations (HMOs) and all pharmacies in Israel, including pharmacy chains. In the future, as regulatory approvals allow, S.L.E. will provide logistics capability for exporting Canndoc’s products to countries that support regulations for the sale and distribution of cannabis products for medical use.

S.L.E. is one of Israel’s leading companies for providing health logistics services and distributes products from dozens of local and international companies. S.L.E. is licensed by the Israeli Ministry of Health, and also holds a GDP distribution license.

“Our agreement with S.L.E., Israel’s leading company in distributing medical products, creates a complete supporting platform for supplying Canndoc’s GMP products to any location in Israel and for countries with similar regulations,” said Canndoc’s Chairman Ehud BarakThrough its S.L.E. partnership, Canndoc has aligned itself with one of the most prominent pharmaceutical companies in the world, for the distribution of cannabis-based medical treatments to countries that recognize the value of these medicines for people in need.”

S.L.E. CEO Aviad Bossi adds, “The agreement brings together our well-established pharmaceutical distribution network with Canndoc’s high quality medical cannabis industry presence and market leadership. Beyond the operations in Israel, this agreement will provide Canndoc significant logistical capabilities that can support Canndoc’s exporting operations from Israel.”

The distribution agreement is set for a 3-year term and includes a mechanism for automatic extension periods of two years each.

Canndoc is one of the first licensed producers, with its GMP-approved medical cannabis Rx products being sold in pharmacies. The engagement in this distribution agreement will broaden Canndoc’s ability to distribute GMP products to its patients within the S.L.E. pharmacy network throughout Israel. In addition, S.L.E. will provide Canndoc significant logistical capabilities in the future supporting Canndoc’s ability to export its products to countries with consistent regulation for the sale and distribution of cannabis products for medical use.

 

SOURCE Canndoc

Continue Reading

Trending Online

Grassnews is a news publishing website which digests / hand picks the latest news about the cannabis industry, and serves them to you daily.

Contact us: pressroom@grassnews.net

© Grassnews.net 2019 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania